Fullscreen
Loading...
 
CYTOPATHNET: Online Resource for Cytopathology > 2006 ASCCP Guidelines

2006 ASCCP Guidelines

exclaim Evidence-based consensus guidelines for the clinical management of women with cervical abnormalities detected during cancer screening were recently developed and published by a multidisciplinary group. This group met on September 18-19, 2006 in Bethesda, Maryland, and consisted of 146 experts and 29 organizations and professional societies. The guidelines were officially released on October 5, 2007. Recommendations for managing atypical squamous cells of undetermined significance and low-grade squamous intraepithelial lesion (LSIL) are essentially unchanged. Changes were made for managing these conditions in adolescents for whom cytological follow-up for 2 years was approved. Recommendations for managing high-grade squamous intraepithelial lesion (HSIL) and atypical glandular cells (AGC) also underwent only minor modifications. More emphasis is placed on immediate screen-and-treat approaches for HSIL. Human papillomavirus (HPV) testing is incorporated into the management of AGC after their initial evaluation with colposcopy and endometrial sampling. The 2004 Interim Guidance for HPV testing as an adjunct to cervical cytology for screening in women 30 years of age and older was formally adopted with only very minor modifications. 1

Brief Overview

What has Changed?
What has Changed?
CategoryType of Change
ASC-US Essentially unchanged
AGC Minor modifications
LSIL Essentially unchanged
HSIL Minor modifications
HPV Testing Formal adoption of 2004 Interim Guidance for HPV testing

The Specifics

How the Recommendations Were Rated
Rating the recommendations
Strength of RecommendationDescription
A Good evidence for efficacy and substantial clinical benefit support recommendation for use.
B Moderate evidence for efficacy or only limited clinical benefit supports recommendation for use.
C Evidence for efficacy is insufficient to support a recommendation for or against use, but recommendations may be made on other grounds.
D Moderate evidence for lack of efficacy or for adverse outcome supports a recommendation against use.
E Good evidence for lack of efficacy or for adverse outcome supports a recommendation against use.
Quality of Evidence*Description
I Evidence from at least 1 randomized, controlled trial.
II Evidence from at least 1 clinical trial without randomization, from cohort or case-controlled analytic studies (preferably from more than 1 center) or from multiple time-series studies or dramatic results from uncontrolled experiments.
III Evidence from opinions of respected authorities based on clinical experience, descriptive studies, or reports of expert committees.
Terminology used for recommendations•Description
Recommended Good data to support use when only 1 option is available.
Preferred Option is the best (or 1 of the best) when there are multiple other options
Acceptable One of multiple options when there are either data indicating that another approach is superior or when there are no
data to favor any single option.
Unacceptable Good data against use.
  • Modified from references 1.

• The assignment of these terms represents an opinion ratified by vote by the Consensus Conference.

 

ASC-US

 

AGC

 

LSIL

 

HSIL

 

HPV Testing

2001 ASCCP Guidelines

2001 ASCCP Guidelines are linked here for reference.

Additional Guidelines

2006 ASCCP Guidelines on Inadequate/Limited Pap Results and Endometrial Cells on Pap

 

ideaEndometrial Cells on Pap: Benign endometrial cells in premenopausal women in the first half of the cycle are not associated with significant pathology and such women do not need additional evaluation. Significant pathology is also unlikely in the second half of the cycle and evaluation may not be required unless clinically indicated. Initial evaluation of other women with benign endometrial cells may include either endometrial sampling or transvaginal ultrasound. Atypical endometrial cells are associated with a higher rate of significant pathology and should lead to additional evaluation. Additional prospective studies on the management of patients with endometrial cells on Pap tests are needed.

  • Prevalence: Benign endometrial cells-accuracy is difficult to assess due to variations in study reporting, varying from 0.5% up to 3% of women 40 years of age or older. Atypical endometrial cells-from 0.03 up to .1%, accounting for up to 5.25% of all glandular abnormalities reported. Overall AGC prevalence reported to be around 0.2%.
  • Morphology: Under Bethesda 2001 criteria, include both glandular and stromal cells exfoliating in ball or gland-like clusters, rarely as single cells. Do not report abraded endometrial cells from lower uterine segment (LUS) or stromal cells and/or histiocytes as they do not carry the same risk for underlying endometrial pathology. Differential diagnosis of atypical endometrial cells includes: benign exfoliated endometrial cells, other types of atypical glandular and squamous processes, and adenocarcinoma. Many biopsies showing endometrial adenocarcinoma will have previous negative cytology or only benign endometrial cells. When the cytology shows malignant endometrial cells, the tumor grade is often higher and clinical stage more advanced.
  • Clinical significance: Benign endometrial cells on cervical cytology are most often associated with benign endometrial pathology (22-97%). Some of the pathology which may be identified include: polyps (1-41%), hyperplasias with (0.6-8%) and without atypia (1-20%), low and high grade adenocarcinomas (1-15%), leiomyomata, atrophy, proliferative endometrium, immediate postpartum state, impending or early post abortion, acute endometritis, recent intrauterine instrumentation, IUD use, and cervical and vaginal endometriosis.

    • Hormone Replacement Therapy (HRT): There is controversy about the effect of hormone replacement therapy (HRT) on postmenopausal women and the presence of normal appearing endometrial cells on Pap tests. Tamoxifen use (>5 years) has been associated with and increased risk of endometrial pathology, including endometrial hyperplasia and adenocarcinoma. For women on Tamoxifen with benign endometrial cells on Pap, additional evaluation is recommended.
  • Management: For immediate follow up, endometrial sampling, hysteroscopic dilation and curettage (D&C), and transvaginal ultrasound with or without sonohysterography are available options.
  • Review of Current Guidelines: 1991 TBS placed the presence of endometrials occuring in the latter half of the cycle of a postmenopausal woman as an epithelial cell abnormality. The 2001 TBS changed this to include the reporting of endometrials cells in a woman over the age of 40, and not as an epithelial cell abnormality. More specific educational notes in the report may be necessary to guide the clinical management in order to reduce unnecessary endometrial evaluation. Clinicians should be advised of the current evidence that supports further evaluation in all postmenopausal women with benign endometrial cells in Pap tests regardless of the presence of symptoms (bleeding)(1-15% risk of carcinoma).
  • Areas of Future Study:

    • Prospective studies needed.
    • Significant pathology should be defined as atypical complex hyperplasia and carcinoma or other malignancies.
    • Randomized assignment to evaluation methods.

 

ideaInadequate/Limited Pap Results: The guidelines recommend a repeat Pap test in 12 months for most women who are undergoing routine annual/biennial screening if the current Pap test is negative but either lacks an endocervical/transformation zone component or is partially obscured. Indications for considering an earlier repeat are also provided. The preferred management for unsatisfactory Pap tests is a repeat Pap test within a short interval of 2 to 4 months.

References

1. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests Thomas C. Wright , L. Stewart Massad , Charles J. Dunton , Mark Spitzer , Edward J. Wilkinson , Diane Solomon American Journal of Obstetrics & Gynecology- 2007 October (Vol. 197, Issue 4, Pages 346-355, DOI: 10.1016/j.ajog.2007.07.047) NOTE: For access to article without fee, choose Article via Elsevier Health Sciences - Elsevier imprints, theclinics.com, and ophsource.org . 2. The 2001 Consensus Guidelines for the Management of Women with Cytological Abnormalities. JAMA (2002;287:2120-2129). American Society for Colposcopy and Cervical Pathology (ASCCP)

 


Contributors to this page: admin .
Page last modified on Wednesday 02 of February, 2011 12:27:16 MST by admin.
The content on this page is licensed under the terms of the Creative Commons Attribution-ShareAlike License.

Search Wiki Page

Exact match

CYTOPATHNET Polls

Do you plan to adopt the Bethesda Guidelines for Thyroid Cytology?






Code of Conduct

We comply with the HONcode standard for health trust worthy information:
verify here.

Theme: Tikinewt

TikiWiki assistant

Thank you for installing Tikiwiki!

LoginTo begin configuring Tiki, please login as admin.

The Tikiwiki CommunityTo learn more, visit: http://tiki.org.

Tikiwiki DocumentationFor help, visit http://doc.tiki.org.

Upcoming events

1)  Tue 12 of May, 2015
National Cytotechnology Day

Online users

98 online users

Search PubMed

PubMed Logo
Search PubMed:   

Shoutbox

kucingz2 points , 02:08 MDT, Tue 06 of May, 2014: http://goo.gl/3n9rax
kucingz2 points , 01:52 MDT, Mon 21 of Apr., 2014: [Link] [Link] [Link] [Link] [Link]
admin, 21:24 MST, Wed 22 of Feb., 2012: User registration enhancements made and more coming in future.
admin, 18:06 MST, Sun 29 of Jan., 2012: Site upgraded from 6.4 to 6.6.
admin, 21:56 MDT, Thu 06 of Oct., 2011: Not sure I totally understand question. Perhaps post to forums for feedback.

Random Image

thumbnail
abk.jpg
Gallery: Breast Cytology

Google Search

 
cytopathnet.org
WWW

Site Language: English